
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Uniqure NV | TG:UQ1 | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|
0.35 | 2.75% | 13.055 | 0.00 | 22:50:13 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
12.855 | 13.25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | 0 | 13.055 | EUR |
Date | Time | Source | Headline |
---|---|---|---|
27/2/2025 | 12:05 | UKREG | uniQure Announces 2024 Financial Results and Highlights Recent Company.. |
03/2/2025 | 12:05 | UKREG | uniQure Announces Completion of Enrollment in the First Cohort and.. |
30/1/2025 | 12:37 | UKREG | uniQure Announces Favorable Recommendation from Independent Data Monitoring.. |
08/1/2025 | 12:05 | UKREG | uniQure Announces Pricing of its Public Offering |
07/1/2025 | 21:49 | UKREG | uniQure Announces Proposed Public Offering |
10/12/2024 | 12:05 | UKREG | uniQure Announces Alignment with FDA on Key Elements of Accelerated.. |
21/11/2024 | 12:05 | UKREG | uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical.. |
05/11/2024 | 12:05 | UKREG | uniQure Announces Third Quarter 2024 Financial Results and Highlights.. |
15/10/2024 | 11:05 | UKREG | uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of.. |
23/9/2024 | 11:05 | UKREG | uniQure Announces Orphan Drug Designation Granted to AMT-191 for the.. |
Uniqure NV (UQ1) Share Charts1 Year Uniqure NV Chart |
|
1 Month Uniqure NV Chart |
Intraday Uniqure NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions